Preventing serious sequelae after an acute coronary syndrome: The consequences of thrombosis versus bleeding with antiplatelet therapy

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 6, 2010, Pages 585-594

  Islam, Ashequl M ^a   Patel, Pranav M ^b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute coronary syndrome; aspirin; bleeding; clopidogrel; ischemic events; prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CIMETIDINE; CLOPIDOGREL; OMEPRAZOLE; PRASUGREL; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; BLEEDING; CORONARY ARTERY BYPASS GRAFT; DRUG MEGADOSE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION COST; HUMAN; MORBIDITY; MORTALITY; NEUTROPENIA; PATIENT EDUCATION; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; THROMBOSIS; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COMPLICATION; HEMORRHAGE;

ACUTE CORONARY SYNDROME; ASPIRIN; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY BYPASS; HEMORRHAGE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RISK FACTORS; THIOPHENES; THROMBOSIS; TICLOPIDINE;

EID: 77953811193     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181d9f81f     Document Type: Review

References (82)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148-e304.
2. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005; 46:937-954.
3. Depta JP, Bhatt DL. Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance. Am J Cardiovasc Drugs. 2008;8:91-112.
4. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation. 2004;110:e82-e292.
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
6. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372. (Pubitemid 43947981)
7. Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf. 1998;19:89-98.
8. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee. Circulation. 2008;117:261-295.
9. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354:1706-1717.
10. Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med. 2001;345:494-502.
11. Chen ZM, Jiang LX, Chen YP, et al; COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-1621.
12. Steinhubl SR, Berger PB, Mann JT III, et al; CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
13. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-2383.
14. Toth PP. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Postgrad Med. 2009;121:59-72.
15. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing committee to update 2001 guidelines for percutaneous coronary intervention). Circulation. 2006;113:e166-e286.
16. Zimmermann N, Gams E, Hohlfeld T. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur J Cardiothorac Surg. 2008;34:93-108.
17. Kulik A, Voisine P, Tardif J, et al. Clopidogrel and aspirin versus aspirin alone after coronary bypass surgery: results from the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) randomized controlled trial [AHA abstract 128]. Presented at American Heart Association, November 16, 2009, Orlando, FL.
18. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
19. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. 2004;164:2106-2110.
20. Fox KA, Anderson FA Jr, Goodman SG, et al; GRACE Investigators. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med. 2008;5:580-589.
21. Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. Circulation. 1998;98:1860-1868.
22. Applegate RJ, Sacrinty MT, Little WC, et al. Incidence of coronary stent thrombosis based on academic research consortium definitions. Am J Cardiol. 2008;102:683-688.
23. Inoue T, Sohma R, Miyazaki T, et al. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol. 2000;86:1057-1062.
24. Budaj A, Flasinska K, Gore JM, et al. Magnitude of and risk factors for inhospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. Circulation. 2005;111:3242-3247.
25. Capewell S, Murphy NF, MacIntyre K, et al. Short-term and long-term outcomes in 133,429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990-2000: population-based cohort study. Heart. 2006;92:1563-1570.
26. Devlin G, Anderson FA, Heald S, et al. Management and outcomes of lower risk patients presenting with acute coronary syndromes in a multinational observational registry. Heart. 2005;91:1394-1399.
27. Kassem-Moussa H, Mahaffey KW, Graffagnino C, et al. Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. Am Heart J. 2004;148:439-446.
28. Lansky AJ, Pietras C, Costa RA, et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2005;111:1611-1618.
29. Gurbel PA, Bliden KP, Cohen E, et al. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagul Fibrinolysis. 2008;19:268-275.
30. Catella-Lawson F. Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology. 2001;57:S5-S7.
31. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980-1987.
32. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007; 154:221-231.
33. Kong DF. Aspirin in cardiovascular disorders. What is the optimum dose? Am J Cardiovasc Drugs. 2004;4:151-158.
34. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195-198.
35. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost. 2007;98:838-843.
36. Morel O, Bernhard N, Desprez D, et al. Residual prothrombotic status in low responder patients to clopidogrel identified by vasodilator-stimulated phosphoprotein phosphorylation (VASP) analysis? Thromb Haemost. 2008;99:448-451.
37. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153: 66, e9-e16.
38. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
39. Plavix [package insert]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceutical; 2009.
40. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
41. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260.
42. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009;43: 1266-1274.
43. Gupta E, Bansal D, Sotos J, et al. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2009 [Epub ahead of print].
44. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714-719.
45. Food and Drug Administration. Public Health Advisory: updated safety information about a drug between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdviso ries/ucm190825.htm. Accessed November 23, 2009.
46. Bhatt D, Cryer B, Contant C, et al. COGENT: a prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Presented at 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) Meeting, September 24, 2009, San Francisco, CA.
47. Mehta S.OASIS7 trial results: a randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus lowdose aspirin in 25,000 patients with acute coronary syndromes. Presented at European Society of Cardiology, August 30, 2009, Barcelona, Spain.
48. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol. 2008;52:1968-1977.
49. Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol. 2007;63: 421-430.
50. Jakubowski JA, Payne CD, Weerakkody GJ, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol. 2007;49: 167-173.
51. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009; 119:2553-2560.
52. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92:930-935.
53. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events GRACE. Eur Heart J. 2003;24:1815-1823.
54. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007;116:2793-2801.
55. Labinaz M, Ho C, Banerjee S, et al. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol. 2007;23:963-970.
56. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201-206.
57. Bassand JP. Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm. Heart. 2008;94:661-666.
58. Berger PB, Manoukian SV. Bleeding is bad.. isn't it? Circulation. 2007; 116:2776-2778.
59. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006; 114:774-782.
60. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patientswith acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007;49:1362-1368.
61. Serebruany VL, Midei MG, Meilman H, et al. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed noncompliance in patient enrolled in the JUMBO trial. Int J Clin Pract. 2006; 60:863-866.
62. Gibson CM. Antiplatelet therapy: anti-ischemic benefits versus bleeding risk. J Interv Cardiol. October 24, 2008;21:S3-S9.
63. Eisenstein EL, Cowper PA, Bae JP, et al. What is the clinical benefit of preventing non-fatal myocardial infarctions? Presented at International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress, October 24, 2008, Athens, Greece.
64. Doucet J, Greboval-Furstenfeld E, Tavildari A, et al. Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Fundam Clin Pharmacol. 2008;22:569-574.
65. Bottorff MB, Nutescu EA, Spinler S, et al. Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative. Pharmacotherapy. 2007;27:1145-1162.
66. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49:734-739.
67. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35: 1288-1294.
68. Nasser M, Kapeliovich M, Markiewicz W. Late thrombosis of sirolimuseluting stents following noncardiac surgery. Catheter Cardiovasc Interv. 2005;65:516-519.
69. Sharma AK, Ajani AE, Hamwi SM, et al. Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv. 2004;63:141-145.
70. Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004;62:1187-1189.
71. Rao SV, Kaul PR, Liao L, et al. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008;155:369-374.
72. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med. 2005;142: 251-259.
73. Mahoney EM, Wang K, Arnold SV, et al. Index, follow-up and total hospitalization costs in patients with acute coronary syndromes undergoing planned percutaneous coronary intervention treated with prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Presented at International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress, October 24, 2008, Athens, Greece.
74. Wiviott SD, Antman EM, Winters KJ, et al; JUMBO-TIMI Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005; 111:3366-3373.
75. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
76. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371:1353-1363.
77. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723-731.
78. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118:1626-1636.
79. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med. 2007;357:2078-2081.
80. Division of Cardiovascular and Renal Products. Revised Secondary CDTL Review for NDA 22-307. EFFIENTTM (prasugrel hydrochloride) Tablets. Food and Drug Administration Center for Drug Evaluation and Research; January 9, 2009.
81. Liberopoulos EN, Elisaf MS, Tselepis AD, et al. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now? Platelets. 2006;17:1-6.
82. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-1687.